Medical Oncology Department, Centre François Baclesse, CHU Côte de Nacre, Caen, France.
Medical Oncology Department, Hôpital Européen Georges Pompidou, Paris Descartes University, Paris, France.
Clin Genitourin Cancer. 2020 Oct;18(5):e510-e516. doi: 10.1016/j.clgc.2020.02.003. Epub 2020 Mar 6.
This prospective study collected quality of life (QoL) and pain data during cabazitaxel treatment in patients with advanced metastatic or castration-resistant prostate cancer (mCRPC).
Functional Assessment of Cancer Therapy-Prostate (QoL) and Brief Pain Inventory-Short Form (pain) questionnaires were collected over 6 months.
In 61 patients with mCRPC (median age, 72 years) from 22 centers, metastatic sites were bones (97%), lymph nodes (36%), and visceral (20%); 25% received cabazitaxel in the second line, 29% in the third line, and 46% in the fourth line or beyond. All had been previously treated with docetaxel, except one with paclitaxel, and 75% also with abiraterone, enzalutamide, or both. The median cabazitaxel duration was 3.4 months. Forty-nine patients were evaluable for QoL and 44 for pain. QoL was improved in 37%, maintained in 35%, and deteriorated in 37%. In 27%, pain decreased ≥ 1 level and remained stable in 52%. A total of 34% lowered analgesic drug level. Prostate-specific antigen response ≥ 50% was observed in 11 (32.6%) patients, of whom 7 improved QoL and 1 was stable. At 6 months, 83.6% survived (95% confidence interval, 71.7%-90.8%). A total of 46% had ≥ 1 grade ≥ 3 adverse events, mainly anemia and neutropenia.
Although cabazitaxel was given as the third line and beyond for three-quarters of patients, over one-third had improved QoL and/or decreased pain during treatment.
本前瞻性研究收集了卡巴他赛治疗晚期转移性或去势抵抗性前列腺癌（mCRPC）患者的生活质量（QoL）和疼痛数据。
在 6 个月的时间内，收集了癌症治疗功能评估-前列腺（QoL）和简明疼痛量表-短表（疼痛）问卷。
在来自 22 个中心的 61 例 mCRPC 患者（中位年龄 72 岁）中，转移部位为骨骼（97%）、淋巴结（36%）和内脏（20%）；25%的患者二线接受卡巴他赛治疗，29%的患者三线接受治疗，46%的患者四线或以上接受治疗。除 1 例外，所有患者均曾接受多西他赛治疗，75%的患者还曾接受阿比特龙、恩杂鲁胺或两者联合治疗。卡巴他赛的中位持续时间为 3.4 个月。49 例患者可评估 QoL，44 例患者可评估疼痛。37%的患者 QoL 改善，35%的患者 QoL 保持稳定，37%的患者 QoL 恶化。27%的患者疼痛下降≥1 级且保持稳定。共有 34%的患者降低了镇痛药水平。11 例（32.6%）患者前列腺特异性抗原反应≥50%，其中 7 例患者 QoL 改善，1 例患者 QoL 稳定。6 个月时，83.6%的患者存活（95%置信区间，71.7%-90.8%）。共有 46%的患者发生≥1 次≥3 级不良事件，主要为贫血和中性粒细胞减少。
尽管四分之三的患者接受卡巴他赛治疗的时间为三线及以上，但仍有超过三分之一的患者在治疗期间 QoL 得到改善和/或疼痛减轻。
